Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American

Drug Metabolism and Disposition

Volumn 33, Issue 3, 2005, Pages 458-465

  Kaniwa, Nahoko ^a   Kurose, Kouichi ^a   Jinno, Hideto ^a   Tanaka Kagawa, Toshiko ^a   Saito, Yoshiro ^a   Saeki, Mayumi ^a   Sawada, Jun Ichi ^a   Tohkin, Masahiro ^a   Hasegawa, Ryuichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PHENOBARBITAL;

3' UNTRANSLATED REGION; AFRICAN AMERICAN; ANIMAL CELL; ARTICLE; ASIAN AMERICAN; CAUCASIAN; CELL STRAIN COS1; CONTROLLED STUDY; DNA FLANKING REGION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DETOXIFICATION; DRUG GLUCURONIDATION; DRUG STABILITY; EXON; GENE FREQUENCY; GENETIC LINKAGE; GENETIC TRAIT; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPERBILIRUBINEMIA; MONKEY; NONHUMAN; NORMAL HUMAN; POPULATION; PRIORITY JOURNAL; RACE DIFFERENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TATA BOX; WESTERN BLOTTING; WILD TYPE;

AFRICAN AMERICANS; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; CERCOPITHECUS AETHIOPS; COS CELLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 14044279224     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001800     Document Type: Article

References (34)

1. Acuna G, Foernzler D, Leong D, Rabbia M, Smit R, Dorflinger E, Gasser R, Hoh J, Ott J, Borroni E, et al. (2002) Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2:327-334.
2. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926.
3. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, and Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702.
4. Beutler E, Gelbart T, and Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
6. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, and Ethell B (2000) Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases. Toxicol Lett 112-113:333-340.
7. Conne B, Stutz A, and Vassalli JD (2000) The 3′ untranslated region of messenger RNA: a molecular "hotspot" for pathology? Nat Med 6:637-641.
8. Day DA and Tuite MF (1998) Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol 157:361-371.
9. Fertrin KY, Goncalves MS, Saad ST, and Costa FF (2002) Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 108:117-119.
10. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, and Sawada J (2001) Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31:687-699.
11. Huang CS, Luo GA, Huang ML, Yu SC, and Yang SS (2000) Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. 10:539-544.
12. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ, and Di Rienzo A (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733.
13. Iolascon A, Faienza MF, Centra M, Storelli S, Zelante L, and Savoia A (1999) TA8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Haematologica 84:106-109.
14. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
15. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
16. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 101:847-854.
17. Jinno H, Hanioka N, Tanaka-Kagawa T, Saito Y, Ozawa S, and Sawada J (2005) Transfection assays with allele specific constructs: functional analysis of UDP-glucuronosyltransferase variants, in Methods in Molecular Biology, Vol. 311: Pharmacogenomics: Methods and Applications (Innocenti F ed), Humana Press Inc., Totowa, NJ, in press.
18. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, et al. (2003a) Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306:688-693.
19. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, and Sawada J (2003b) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31:108-113.
20. Judson R, Stephens JC, and Windemuth A (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1:15-26.
21. Ki CS, Lee KA, Lee SY, Kim HJ, Cho SS, Park JH, Cho S, Sohn KM, and Kim JW (2003) Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin Chem 49:2078-2081.
22. Koiwai O, Nishizawa M, Hasada K, Aono S, Adachi Y, Mamiya N, and Sato H (1995) Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 4:1183-1186.
23. Kraemer D and Klinker H (2002) Crigler-Najjar syndrome type II in a Caucasian patient resulting from two mutations in the bilirubin uridine 5′-diphosphate-glucuronosyltransferase (UGT1A1) gene. J Hepatol 36:706-707.
24. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
25. Premawardhena A, Fisher CA, Liu YT, Verma IC, de Silva S, Arambepola M, Clegg JB, and Weatherall DJ (2003) The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase I gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 31:98-101.
26. Raijmakers MT, Jansen PL, Steegers EA, and Peters WH (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33:348-351.
27. Saeki M, Ozawa S, Saito Y, Jinno H, Hamaguchi T, Nokihara H, Shimada Y, Kunitoh H, Yamamoto N, Ohe Y, et al. (2002) Three novel single nucleotide polymorphisms in UGT1A10. Drug Metab Pharmacokinet 17:488-490.
28. Saeki M, Saito Y, Jinno H, Tohkin M, Kurose K, Kaniwa N, Komamura K, Ueno K, Kamakura S, Kitakaze M, et al. (2003) Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin Chem 49:1182-1185.
29. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, et al. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515.
30. Stephens M and Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
31. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
32. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, and Miwa M (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292:492-497.
33. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
34. Yamamoto A, Nishio H, Waku S, Yokoyama N, Yonetani M, Uetani Y, and Nakamura H (2002) Gly71Arg mutation of the bilirubin UDP-glucuronosyltransferase 1A1 gene is associated with neonatal hyperbilirubinemia in the Japanese population. Kobe J Med Sci 48:73-77.